-
1
-
-
33646504948
-
Adrenergic and muscarinergic blockade and the cardiovascular effects of exogenously administered and endogenously released noradrenaline in humans
-
Schäfers R.F., Poller U., Ponicke K., Geissler M., Dad A.E., Michel M.C., and Brodde O.-E. Adrenergic and muscarinergic blockade and the cardiovascular effects of exogenously administered and endogenously released noradrenaline in humans. Naunyn Schmiedebergs Arch. Pharmacol 335 (1996) 239-249
-
(1996)
Naunyn Schmiedebergs Arch. Pharmacol
, vol.335
, pp. 239-249
-
-
Schäfers, R.F.1
Poller, U.2
Ponicke, K.3
Geissler, M.4
Dad, A.E.5
Michel, M.C.6
Brodde, O.-E.7
-
3
-
-
0030008944
-
Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned α 1-adrenoceptor subtypes and in human prostate
-
Michel M.C., Grübbel B., Taguchi K., Verfürth F., Otto T., and Kröpfl D. Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned α 1-adrenoceptor subtypes and in human prostate. J. Auton. Pharmacol 16 (1996) 21-28
-
(1996)
J. Auton. Pharmacol
, vol.16
, pp. 21-28
-
-
Michel, M.C.1
Grübbel, B.2
Taguchi, K.3
Verfürth, F.4
Otto, T.5
Kröpfl, D.6
-
4
-
-
0030046789
-
RS-17053 (N-[2-cyclopropylmethoxy-phenoxy)-ethyl]-5-chloro-α,α-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective α 1A,-adrenoceptor antagonist, displays low affinity for functional α 1A,-adrenoceptors in human prostate: Implications for adrenoceptor classification
-
Ford A.P.D.W., Arredondo N.F., Blue D.R., Bouhaus D.W., Jasper J.R., Kava M.S., Lesnick J., Pfister J.R., Shiely I.A., Vimont R.L., Williams T.J., McNeal J.E., Stamey T.A., and Clarke D.E. RS-17053 (N-[2-cyclopropylmethoxy-phenoxy)-ethyl]-5-chloro-α,α-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective α 1A,-adrenoceptor antagonist, displays low affinity for functional α 1A,-adrenoceptors in human prostate: Implications for adrenoceptor classification. Mol. Pharmacol 49 (1996) 209-215
-
(1996)
Mol. Pharmacol
, vol.49
, pp. 209-215
-
-
Ford, A.P.D.W.1
Arredondo, N.F.2
Blue, D.R.3
Bouhaus, D.W.4
Jasper, J.R.5
Kava, M.S.6
Lesnick, J.7
Pfister, J.R.8
Shiely, I.A.9
Vimont, R.L.10
Williams, T.J.11
McNeal, J.E.12
Stamey, T.A.13
Clarke, D.E.14
-
5
-
-
0029951323
-
SB 216469, an antagonist which discriminates between the α 1A,-adrenoceptor and the human prostatic α 1-adrenoceptor
-
Chess-Williams R., Chapple C.R., Verfürth F., Noble A.J., Couldwell C.J., and Michel M.C. SB 216469, an antagonist which discriminates between the α 1A,-adrenoceptor and the human prostatic α 1-adrenoceptor. Br. J. Pharmacol 119 (1996) 1093-1100
-
(1996)
Br. J. Pharmacol
, vol.119
, pp. 1093-1100
-
-
Chess-Williams, R.1
Chapple, C.R.2
Verfürth, F.3
Noble, A.J.4
Couldwell, C.J.5
Michel, M.C.6
-
6
-
-
0001645431
-
Whole-cell radioligand binding assay reveals alL-adrenoceptor (AR) antagonist profile for the human cloned α 1A-AR in Chinese hamster ovary (CHO-K1) cells
-
Suppl.
-
Williams T.J., Clarke D.E., and Ford A.P.D.W. Whole-cell radioligand binding assay reveals alL-adrenoceptor (AR) antagonist profile for the human cloned α 1A-AR in Chinese hamster ovary (CHO-K1) cells. Br. J. Pharmacol. 119 (1996) 359 Suppl.
-
(1996)
Br. J. Pharmacol.
, vol.119
, pp. 359
-
-
Williams, T.J.1
Clarke, D.E.2
Ford, A.P.D.W.3
|